BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 932 filers reported holding BAXTER INTL INC in Q1 2023. The put-call ratio across all filers is 0.56 and the average weighting 0.1%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $58,615,500 | +44.1% | 1,150,000 | +52.2% | 1.41% | +34.2% |
Q3 2022 | $40,691,000 | -9.7% | 755,500 | +7.7% | 1.05% | -19.8% |
Q2 2022 | $45,064,000 | -22.6% | 701,600 | -6.5% | 1.31% | -10.5% |
Q1 2022 | $58,209,000 | -7.6% | 750,700 | +2.3% | 1.46% | +0.7% |
Q4 2021 | $62,990,000 | +74.0% | 733,803 | +63.1% | 1.46% | +91.2% |
Q3 2021 | $36,194,000 | +206.5% | 450,000 | +221.4% | 0.76% | +195.0% |
Q1 2021 | $11,808,000 | -51.1% | 140,000 | -53.5% | 0.26% | -49.6% |
Q4 2020 | $24,152,000 | -53.4% | 301,000 | -53.3% | 0.51% | -61.1% |
Q3 2020 | $51,871,000 | -6.6% | 645,000 | 0.0% | 1.32% | -13.6% |
Q2 2020 | $55,535,000 | +6.0% | 645,000 | 0.0% | 1.52% | -29.7% |
Q1 2020 | $52,368,000 | +19.3% | 645,000 | +22.9% | 2.16% | +56.1% |
Q4 2019 | $43,901,000 | +30.4% | 525,000 | +36.4% | 1.39% | +3.4% |
Q3 2019 | $33,676,000 | +36.7% | 385,000 | +28.0% | 1.34% | +50.6% |
Q2 2019 | $24,627,000 | +0.7% | 300,700 | 0.0% | 0.89% | -5.5% |
Q1 2019 | $24,450,000 | +23.5% | 300,700 | 0.0% | 0.94% | +1.0% |
Q4 2018 | $19,792,000 | -13.6% | 300,700 | +1.2% | 0.93% | +12.7% |
Q3 2018 | $22,896,000 | +4.4% | 297,000 | 0.0% | 0.83% | -1.8% |
Q2 2018 | $21,930,000 | +13.5% | 297,000 | 0.0% | 0.84% | +2.4% |
Q1 2018 | $19,317,000 | +29.9% | 297,000 | +29.1% | 0.82% | +22.1% |
Q4 2017 | $14,867,000 | +3.0% | 230,000 | 0.0% | 0.68% | +1.4% |
Q3 2017 | $14,433,000 | +3.7% | 230,000 | 0.0% | 0.67% | -5.3% |
Q2 2017 | $13,924,000 | – | 230,000 | – | 0.70% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |